Provision as per the 1/2 yearly.
Update to the status of the Contingent Consideration (Earn-outs)
• Earn-out 1
Condition: CY2024 revenue: Within 120 days after the end of CY2024, 4DMedical will pay the Sellers an
amount equal to four times the incremental revenue growth (over US$3.5 million) of Imbio products in
CY2024 from eligible forecasted CY2023 revenue, up to a cap of US$2.5 million of incremental revenue
growth for a maximum Earnout payment of US$10 million.
Status: 4DMedical recognised 50% (US$5.0m) of Earn-out 1 as part of the acquisition accounting. The
conditions to trigger payment of Earn-out 1 were not met. The reduction in 4DMedical's contingent
consideration was recognised in the P&L as a Gain on remeasurement of Contingent Consideration
Liability as Other Comprehensive Income (AU$7.9m)
- Forums
- ASX - By Stock
- 4DX
- Ann: Cleansing Notice
4DX
4dmedical limited
Add to My Watchlist
3.85%
!
25.0¢

Ann: Cleansing Notice, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $116.3M |
Open | High | Low | Value | Volume |
25.5¢ | 26.0¢ | 25.0¢ | $190.5K | 753.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 78598 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 46681 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 54658 | 0.250 |
8 | 32660 | 0.245 |
12 | 123123 | 0.240 |
8 | 354728 | 0.235 |
17 | 521612 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 46681 | 1 |
0.265 | 15419 | 3 |
0.270 | 64703 | 3 |
0.275 | 110821 | 6 |
0.280 | 159939 | 6 |
Last trade - 16.11pm 25/07/2025 (20 minute delay) ? |
Featured News
4DX (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online